Severe Obesity Clinical Trial
— BESTOfficial title:
Bypass Equipoise Sleeve Trial (BEST); A Randomised Controlled Multicenter Trial Comparing Gastric Bypass and Sleeve Gastrectomy
Verified date | February 2024 |
Source | Göteborg University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is nationwide registry-based randomised clinical multicenter trial in which patients will be randomised to gastric bypass (RYGB) or sleeve gastrectomy (SG). The co-primary endpoint are weight control over 5 years and the amount of severe adverse events. Additionally the investigators have predefined a number of secondary endpoints, and the trial has a sufficient number of patients to allow comparisons across subgroups.
Status | Active, not recruiting |
Enrollment | 1752 |
Est. completion date | December 2031 |
Est. primary completion date | December 2026 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 70 Years |
Eligibility | Inclusion Criteria: - BMI 35-50 kg/m2 - Ability to understand and decide on the merits of the study participation - Accepted for bariatric surgery - Must understand the information, and be able to make a decisions about participation in the study Exclusion Criteria: - Previous bariatric surgery, anti reflux surgery or other gastric surgery - Moderate to severe reflux disease, Barretts oesophagus or known hiatus hernia >4 cm - Unstable mental illness or other known contraindication to bariatric surgery. - Planned significant surgery at the same time - Inflammatory bowel disease - ongoing drug or substance abuse - not appropriate to randomise the patient, according to surgeon |
Country | Name | City | State |
---|---|---|---|
Norway | Sentralsykehuset Vestfold | Tønsberg | |
Sweden | Falu Hospital | Falun | |
Sweden | Gävle Hospital | Gävle | |
Sweden | Östra Hospital | Göteborg | |
Sweden | Kalmar County Hospital | Kalmar | |
Sweden | Lindesbergs Hospital | Lindesberg | |
Sweden | Linköping University | Linköping | |
Sweden | Ljungby Hospital | Ljungby | |
Sweden | Lycksele Hospital | Lycksele | |
Sweden | Mora Hospital | Mora | |
Sweden | Vrinnevi Hospital, Norrköping | Norrköping | |
Sweden | Örebro University Hospital | Örebro | |
Sweden | GB Obesitas | Skåne | |
Sweden | Skaraborgs Hospital | Skövde | |
Sweden | Södertälje Hospital | Södertälje | |
Sweden | Capio S:t Görans Hospital | Stockholm | |
Sweden | Danderyds Hospital | Stockholm | |
Sweden | Ersta Hospital | Stockholm | |
Sweden | Stockholm South General Hospital | Stockholm | |
Sweden | Torsby Hospital | Torsby | |
Sweden | Uppsala University Hospital | Uppsala |
Lead Sponsor | Collaborator |
---|---|
Göteborg University | Capio S:t Görans Hospital, Danderyd Hospital, Ersta Hospital, Sweden, Falu Hospital, Gävle Hospital, GB Obesitas Skane, Gjövik Hospital, Norway, Kalmar County Hospital, Lindesbergs Hospital, Ljungby Hospital, Lycksele Hospital, Mora Hospital, Östra Hospital, Region Örebro County, Skaraborg Hospital, Sodertalje Hospital, Stockholm South General Hospital, Sykehuset i Vestfold HF, Torsby Hospital, Uppsala University Hospital, Vrinnevi Hospital, Norrköping |
Norway, Sweden,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Weight loss | Non-inferiority for SG is defined as < 5% weight difference | 5 years | |
Primary | Serious adverse events | Superiority for SG is having 35% less serious (substantial) adverse events compared to RYGB | 5 years | |
Secondary | Adverse events | General description of patterns of all adverse events | 1, 2, 5 and 10 years | |
Secondary | Weight loss | Between baseline and 1 and 2 years | Baseline, 1, 2, 5 and 10 years | |
Secondary | Number of patients with arterial cardiovascular events | Composite of myocardial infarction+ stroke+ other occlusive arterial condition | Baseline, 1, 2, 5 and 10 years | |
Secondary | Number of patients with venous event | Composite of Deep vein thrombosis+ Pulmonary emboli+ other venous event | Baseline, 1, 2, 5 and 10 years | |
Secondary | Number of patients with diabetes requiring drug treatment | Development of diabetes measured as numbers of patients having a diabetes diagnosis and oral medication and injection therapy | Baseline, 1, 2, 5 and 10 years | |
Secondary | Number of patients with a psychiatric morbidity | Number of patients with a psychiatric morbidity | Baseline, 1, 2, 5 and 10 years | |
Secondary | Number of patients with hypertension treatment | Number of patients with hypertension treatment (any type of Medical treatment) | Baseline, 1, 2, 5 and 10 years | |
Secondary | Number of patients diagnosed with a malignancy | Number of patients diagnosed with a malignancy | Baseline, 1, 2, 5 and 10 years | |
Secondary | Number of patients with dyslipidemia treatment | Number of patients with diagnosis of dyslipidemia and on oral lipid lowering treatment | Baseline, 1, 2, 5 and 10 years | |
Secondary | Weight in men and women | Analyses of the primary outcome weight in men and women | Baseline, 1, 2, 5 and 10 years | |
Secondary | serious adverse events in men and women | Analyses of the primary outcome serious adverse events in men and women | Baseline, 1, 2, 5 and 10 years | |
Secondary | Weight in patients with BMI >43 vs <43 kg/m2. | Analyses of the primary outcome weight in patients with BMI >43 vs <43 kg/m2. | Baseline, 1, 2, 5 and 10 years | |
Secondary | Serious adverse events in patients with BMI >43 vs <43 kg/m2 | Analyses of the primary outcome serious adverse events in patients with BMI >43 vs <43 kg/m2. | Baseline, 1, 2, 5 and 10 years | |
Secondary | Weight in patients aged 18-25 y, 25-50 y, or >50 y | Analyses of the primary outcome weight in patients aged 18-25 y, 25-50 y, or >50 y | Baseline, 1, 2, 5 and 10 years | |
Secondary | Serious adverse events in patients aged 18-25 y, 25-50 y, or >50 y | Analyses of the primary outcome serious adverse events in patients aged 18-25 y, 25-50 y, or >50 y | Baseline, 1, 2, 5 and 10 years | |
Secondary | Mineral nutritional status | Serum concentrations of iron depots, zinc, magnesium, selenium and copper | Baseline, 1, 2, 5 and 10 years | |
Secondary | Vitamin nutritional status | Serum concentrations of vitamins (Vitamin B12, Vitamin D, Vitamin A, thiamin) | Baseline, 1, 2, 5 and 10 years | |
Secondary | Serum concentrations of albumin | Serum concentrations of Albumin | Baseline, 1, 2, 5 and 10 years | |
Secondary | Changes in quality of Life assessed with EQ-5D | Assessed with EQ-5D | Baseline, 1, 2, 5 and 10 years | |
Secondary | Changes in quality of Life assessed with Obesity Problems (OP) | Assessed with Obesity Problems (OP) | Baseline, 1, 2, 5 and 10 years | |
Secondary | Changes in quality of Life assessed with Short Form-36 | Assessed with SF-36 | Baseline, 1, 2, 5 and 10 years | |
Secondary | Alcohol consumption | Assessed by AUDIT | 1, 2, 5 and 10 years | |
Secondary | Gastro-esophageal reflux disease | Gastro-esophageal reflux disease is defined as present/ not present in at least one of following modalities: Questionnaire DeMeester score, 24h pH manometry and/or gastroscopy | 1, 2, 5 and 10 years | |
Secondary | Fracture incidence | From clinical data and national registry | 2, 5 and 10 years | |
Secondary | Bone density and body composition | Dual energy X-ray Absorptiometry (DEXA) in at least a subgroup of 500+500 | 10 years | |
Secondary | Mortality and cause of death | National Cause of Death registry | 5, 10, 20 and 30 years | |
Secondary | Health care consumption, In hospital registry | Data from In hospital registry (Days in hospital) | 5, 10, 20 and 30 years | |
Secondary | Health care consumption, | Data from Outpatient registry ( number of visits) | 5, 10, 20 and 30 years | |
Secondary | Health care consumption | National drug registry (type of drug) | 5, 10, 20 and 30 years | |
Secondary | Development of co-morbidities from national registry data | National stroke registry, National Cardiac registry, National Diabetes Registry, Cancer registry | 5, 10, 20, 30 years | |
Secondary | Formal cost effective analysis | Cost per quality-adjusted life-year and life-year) | 5, 10 and 20 years | |
Secondary | Dietary intake | Questionnaire regarding food intake (E14x) | 1 and 10 years | |
Secondary | Eating patterns | Three Factor Eating Questionnaire (TFEQ) | 1 and 10 years | |
Secondary | Gastro-intestinal side effects | Questionnaire: Gastro-intestinal Symptom Rating Score (GSRS) | 1 and 10 years | |
Secondary | Dumping symptoms | Questionnaire: Dumping Symptom Rating Score (DSRS) | 1 and 10 years | |
Secondary | Adverse events | Clinical data combined with national registry data | 30 days postop, 1, 2, 5 and 10 years | |
Secondary | Peri-operative outcome, Complications | Complications; Surgical (minor/major) and medical | Up to 30 days postop | |
Secondary | Peri-operative outcome, surgical time | surgical time (min) | Up to 30 days postop | |
Secondary | Peri-operative outcome, sick leave | sick leave (days) | Up to 30 days postop | |
Secondary | Peri-operative outcome, length of stay | length of stay (days) | Up to 30 days postop |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03690752 -
Adherence to Walking on an Alter G Anti-Gravity Treadmill
|
N/A | |
Recruiting |
NCT05786092 -
Impact of Telemonitoring on Metabolic Variables in Severe Obesity
|
N/A | |
Active, not recruiting |
NCT03249441 -
Compassion-Focused Therapy for People With Severe Obesity.
|
N/A | |
Terminated |
NCT04626232 -
Comparison of the Sleeve Gastrectomy Technique With a Nissen Fundoplication Added to the Conventional Sleeve Gastrectomy Technique in Morbidly Obese Patients
|
N/A | |
Completed |
NCT02952963 -
Effect of Bile Acids and Bile Acid Sequstrants on GLP-1 Secretion After Roux-en-Y Gastric Bypass
|
Phase 4 | |
Active, not recruiting |
NCT02374632 -
Gut Hormones as Mediators of Different Weight Loss Responses After Roux-en-Y Gastric Bypass
|
Phase 4 | |
Active, not recruiting |
NCT04165694 -
Single Anastomosis Duodenal Ileal Bypass (SADI) for Sleeve Revision
|
N/A | |
Not yet recruiting |
NCT06162715 -
GLP-1 Receptor Agonists Post-Bariatric Surgery (GRABS) Feasibility Trial
|
Phase 2 | |
Completed |
NCT05409612 -
Trial Assessing the Immunogenicity and Safety of Two Influenza Vaccine Strategies Among Severe Obese Adult Patients
|
Phase 3 | |
Completed |
NCT03638895 -
Energy Expenditure From ECAL Indirect Calorimeter in a Multicomponent Weight Management Service
|
N/A | |
Not yet recruiting |
NCT05493592 -
Pigeon Peas (Cajanus Cajan) : a Natural Anti-inflammatory Facilitating Weight Loss in Obese Patients Returning to Sport?
|
N/A | |
Completed |
NCT02823561 -
Garcinia Mangostana Extracts in the Management of Weight Loss
|
Phase 4 | |
Completed |
NCT02340247 -
Effects of Bile Acids on GLP-1 Secretion After Roux-en-Y Gastric Bypass
|
Phase 4 | |
Recruiting |
NCT02076880 -
SLEEVEDIAB To Explore the Early and Late Metabolic Effects of Sleeve Gastrectomy in Obese Patients
|
N/A | |
Completed |
NCT04042493 -
Connect for Health Pediatric Weight Management Program
|
N/A | |
Completed |
NCT04129801 -
Muscle Strength in Severe Obese Patients in the Postoperative of Bariatric Surgery
|
||
Completed |
NCT05341414 -
Trajectories of Resilience and Bariatric Surgery Outcomes
|
||
Recruiting |
NCT02710786 -
Comorbidity After Gastric Bypass
|
||
Recruiting |
NCT02409160 -
Sleep and Immune Response in Severe Obese Patients Undergoing Bariatric Surgery.
|
N/A | |
Completed |
NCT00623792 -
Study on Impact of Lifestyle Change and Weight Loss Before Bariatric Surgery
|
N/A |